• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23685455; PubMed=25538140).
  

PubMed=23685455; DOI=10.1038/nature12154
Kaplon J., Zheng L., Meissl K., Chaneton B., Selivanov V.A., Mackay G., van der Burg S.H., Verdegaal E.M.E., Cascante M., Shlomi T., Gottlieb E., Peeper D.S.
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence.
Nature 498:109-112(2013)

PubMed=25502142; DOI=10.1038/ncomms6712; PMCID=PMC4428333
Muller J., Krijgsman O., Tsoi J., Robert L., Hugo W., Song C., Kong X.-J., Possik P.A., Cornelissen-Steijger P.D.M., Geukes Foppen M.H., Kemper K., Goding C.R., McDermott U., Blank C., Haanen J.B.A.G., Graeber T.G., Ribas A., Lo R.S., Peeper D.S.
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Nat. Commun. 5:5712.1-5712.15(2014)

PubMed=25538140; DOI=10.15252/msb.20145450; PMCID=PMC4300494
Smit M.A., Maddalo G., Greig K., Raaijmakers L.M., Possik P.A., van Breukelen B., Cappadona S., Heck A.J.R., Altelaar A.F.M., Peeper D.S.
ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma.
Mol. Syst. Biol. 10:772-772(2014)